[Recent aspects on the use of specific antisera in diagnosis and therapy of acute lymphatic leukaemia in infants (author's transl)].
Acute lymphatic leukaemia (ALL) in infants is a very heterogeneous disease from the immunological point of view. Phaenotyping of leukaemic cells in 138 patients via different immunmarkers has so far allowed subdivision into 6 subgroups. Clinical risk factors and correlations with the immunologically defined subgroups, as well as their significance for prognosis, are demonstrated with the help of 61 examined ALL patients. 90-95% of all acute lymphatic leukaemias can presently be identified via heterologous antisera. After corresponding absorption, these antisera show high cytotoxicity against ALL cells without displaying any aggressivity towards normal haemopoetic stem cells. The authors make therapeutic use of anti-T cell and anti-common ALL (cALL) globulin in autologous bone marrow transplantation. This method involves withdrawal of bone marrow from patients with ALL in complete remission, the marrow being then fractionated, treated with antiserum to destroy residual leukaemic cells, and then cryopreserved. The leukaemia-free bone marrow will thus be available for transplantation in relapse.
D016026:Bone Marrow Transplantation; D002648:Child; D006801:Humans; D007106:Immune Sera; D007116:Immunization, Passive; D007945:Leukemia, Lymphoid / Q000175:diagnosis* / Q000628:therapy; D010641:Phenotype; D014182:Transplantation, Autologous
D007106:Immune Sera
Neuere Aspekte zur Anwendung spezifischer Antiseren bei der Diagnose und Therapie der akuten lymphatischen Leukämie im Kindesalter.